IDH2 and central nervous system cancer: Regarding the IDH mutation status, MTRasym in IDH mutant gliomas was significantly lower than IDH wild-type gliomas (IDH mutant, 1.41% ± 0.41%; IDH wild-type, 1.83% ± 0.48%, P = 7.17 × 10−4, Fig. 3d), consistent with a previous report18.